Gossamer Bio Inc (GOSS)

$0.23 +0.02 (9.38%)
Market Cap 51.14M
Revenue (ttm) 48.47M
Net Income (ttm) -170.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -351.50%
Debt to Equity Ratio 0.00
Volume 13,216,199
Avg Vol 10,487,336
Day's Range N/A - N/A
Shares Out 234.70M
Stochastic %K 27%
Beta 2.15
Analysts Sell
Price Target $3.80

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
redbeamgold
redbeamgold May. 29 at 9:02 PM
$GOSS will any information be put out from the fda June meeting or is that just fda/goss discussing items for September?
0 · Reply
Krystalp9885
Krystalp9885 May. 29 at 8:06 PM
$GOSS after hours we are moving 🙌
1 · Reply
GangsterX
GangsterX May. 29 at 6:42 PM
$GOSS Shix!! Oh mamama oh mamma.. she wants to move
0 · Reply
GangsterX
GangsterX May. 29 at 6:33 PM
$GOSS we will move next week.. no doubt about it baby
0 · Reply
TopTierNewswire
TopTierNewswire May. 29 at 6:29 PM
$PLAB not looking good here. $PDD $GOSS
0 · Reply
ChasingTheDips
ChasingTheDips May. 29 at 2:04 PM
$GOSS are we cooked
0 · Reply
Moneyboy231
Moneyboy231 May. 29 at 1:47 PM
$GOSS whats wrong with this? You can not short or buy?
1 · Reply
Gautengtrader
Gautengtrader May. 29 at 1:17 PM
$GOSS what a dog
0 · Reply
Partyflags
Partyflags May. 29 at 9:08 AM
$GOSS
0 · Reply
Zing43
Zing43 May. 29 at 3:38 AM
$GOSS
0 · Reply
Latest News on GOSS
Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

2026-05-29T09:38:46.000Z - 16 hours ago

Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

Goldman Sachs suspends rating on Gossamer Bio

2026-05-20T20:11:13.000Z - 9 days ago

Goldman Sachs suspends rating on Gossamer Bio

Gossamer Bio price target lowered to 28c from 30c at Barclays

2026-05-19T09:16:47.000Z - 10 days ago

Gossamer Bio price target lowered to 28c from 30c at Barclays

Gossamer Bio Q1 Earnings Call Highlights

May 18, 2026, 9:06 AM EDT - 11 days ago

Gossamer Bio Q1 Earnings Call Highlights

Gossamer Bio Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Earnings Call Transcript: Q1 2026

Gossamer Bio Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Quarterly report: Q1 2026

Gossamer Bio Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Earnings release: Q1 2026

Gossamer Bio Slides: Q1 2026

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Slides: Q1 2026

Gossamer Bio Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 11 days ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio launches exchange offer, consent solicitation

2026-05-18T11:16:03.000Z - 11 days ago

Gossamer Bio launches exchange offer, consent solicitation

Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year

2026-05-18T11:06:46.000Z - 11 days ago

Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year

Gossamer Bio sees cash runway into 1Q27

2026-05-18T11:05:41.000Z - 11 days ago

Gossamer Bio sees cash runway into 1Q27

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

May 18, 2026, 7:05 AM EDT - 11 days ago

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026, 7:00 AM EDT - 11 days ago

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

May 15, 2026, 7:01 AM EDT - 14 days ago

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Gossamer Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Gossamer Bio Proxy statement: Proxy filing

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 20, 2026, 4:30 PM EDT - 5 weeks ago

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 20, 2026, 11:41 AM EDT - 5 weeks ago

Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-03-23T09:15:15.000Z - 2 months ago

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-03-20T20:45:16.000Z - 2 months ago

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:01 PM EDT - 2 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Gossamer Bio Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Gossamer Bio Earnings release: Q4 2025

Gossamer Bio Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Gossamer Bio Annual report: Q4 2025

Gossamer Bio price target lowered to $5 from $10 at H.C. Wainwright

2026-03-06T11:10:19.000Z - 3 months ago

Gossamer Bio price target lowered to $5 from $10 at H.C. Wainwright

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 23, 2026, 11:26 AM EST - 3 months ago

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Gossamer Bio Transcript: Study result

Feb 23, 2026, 8:30 AM EST - 3 months ago

Gossamer Bio Transcript: Study result

Gossamer Bio Press release: Study result

Feb 23, 2026, 8:30 AM EST - 3 months ago

Gossamer Bio Press release: Study result

Gossamer Bio Slides: Study result

Feb 23, 2026, 8:30 AM EST - 3 months ago

Gossamer Bio Slides: Study result

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Feb 23, 2026, 8:11 AM EST - 3 months ago

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Feb 23, 2026, 8:00 AM EST - 3 months ago

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 5:30 PM EST - 5 months ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 24, 2025, 4:01 PM EST - 6 months ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 10:00 AM EST - 7 months ago

Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:01 PM EST - 7 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Gossamer Bio Earnings release: Q3 2025

Gossamer Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Gossamer Bio Quarterly report: Q3 2025

Gossamer Bio Transcript: Emerging Growth Conference

Oct 23, 2025, 3:40 PM EDT - 7 months ago

Gossamer Bio Transcript: Emerging Growth Conference

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:41 AM EDT - 8 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 25, 2025, 7:31 AM EDT - 8 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 22, 2025, 7:31 AM EDT - 8 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 9 months ago

Gossamer Bio Transcript: Cantor Global Healthcare Conference 2025

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 9 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 10 months ago

Gossamer Bio Earnings release: Q2 2025

Gossamer Bio Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 10 months ago

Gossamer Bio Quarterly report: Q2 2025

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio Transcript: Emerging Growth Conference 82

May 22, 2025, 4:25 PM EDT - 1 year ago

Gossamer Bio Transcript: Emerging Growth Conference 82

Gossamer Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Earnings Call Transcript: Q1 2025

Gossamer Bio Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Earnings release: Q1 2025

Gossamer Bio Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Quarterly report: Q1 2025

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gossamer Bio Proxy statement: Proxy Filing

Gossamer Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gossamer Bio Proxy statement: Proxy Filing

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Annual report: Q4 2024

Mar 13, 2025, 10:30 AM EDT - 1 year ago

Gossamer Bio Annual report: Q4 2024

Gossamer Bio Earnings release: Q4 2024

Mar 13, 2025, 10:30 AM EDT - 1 year ago

Gossamer Bio Earnings release: Q4 2024

Gossamer Bio Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Gossamer Bio Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Gossamer Bio Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 4:20 PM EDT - 1 year ago

Gossamer Bio Transcript: Leerink’s Global Healthcare Conference 2025

Gossamer Bio Transcript: Emerging Growth Conference 79

Feb 19, 2025, 12:00 PM EST - 1 year ago

Gossamer Bio Transcript: Emerging Growth Conference 79

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:30 AM EST - 1 year ago

Gossamer Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Gossamer Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 11, 2024, 10:30 AM EST - 1 year ago

Gossamer Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

Gossamer Bio Earnings release: Q3 2024

Gossamer Bio Quarterly report: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

Gossamer Bio Quarterly report: Q3 2024

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Slides: FY 2024

Aug 14, 2024, 1:42 PM EDT - 1 year ago

Gossamer Bio Slides: FY 2024

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Quarterly report: Q2 2024

Aug 12, 2024, 10:01 AM EDT - 1 year ago

Gossamer Bio Quarterly report: Q2 2024

Gossamer Bio Earnings release: Q2 2024

Aug 12, 2024, 10:01 AM EDT - 1 year ago

Gossamer Bio Earnings release: Q2 2024

Gossamer Bio Transcript: Presents at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 1:20 PM EDT - 2 years ago

Gossamer Bio Transcript: Presents at Goldman Sachs 45th Annual Global Healthcare Conference

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Quarterly report: Q1 2024

May 7, 2024, 10:01 AM EDT - 2 years ago

Gossamer Bio Quarterly report: Q1 2024

Gossamer Bio Earnings release: Q1 2024

May 7, 2024, 10:01 AM EDT - 2 years ago

Gossamer Bio Earnings release: Q1 2024

Gossamer Bio Transcript: M&A Announcement

May 6, 2024, 8:30 AM EDT - 2 years ago

Gossamer Bio Transcript: M&A Announcement

Gossamer Bio Transcript: Collaboration with Chiesi Farmaceutici S.p.A. 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Gossamer Bio Transcript: Collaboration with Chiesi Farmaceutici S.p.A. 2024

Gossamer Bio Slides: FY 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Gossamer Bio Slides: FY 2024

Gossamer Bio Press release: M&A Announcement

May 6, 2024, 8:30 AM EDT - 2 years ago

Gossamer Bio Press release: M&A Announcement

Gossamer Bio Slides: M&A Announcement

May 6, 2024, 8:30 AM EDT - 2 years ago

Gossamer Bio Slides: M&A Announcement

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:46 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6, 2024, 7:30 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

redbeamgold
redbeamgold May. 29 at 9:02 PM
$GOSS will any information be put out from the fda June meeting or is that just fda/goss discussing items for September?
0 · Reply
Krystalp9885
Krystalp9885 May. 29 at 8:06 PM
$GOSS after hours we are moving 🙌
1 · Reply
GangsterX
GangsterX May. 29 at 6:42 PM
$GOSS Shix!! Oh mamama oh mamma.. she wants to move
0 · Reply
GangsterX
GangsterX May. 29 at 6:33 PM
$GOSS we will move next week.. no doubt about it baby
0 · Reply
TopTierNewswire
TopTierNewswire May. 29 at 6:29 PM
$PLAB not looking good here. $PDD $GOSS
0 · Reply
ChasingTheDips
ChasingTheDips May. 29 at 2:04 PM
$GOSS are we cooked
0 · Reply
Moneyboy231
Moneyboy231 May. 29 at 1:47 PM
$GOSS whats wrong with this? You can not short or buy?
1 · Reply
Gautengtrader
Gautengtrader May. 29 at 1:17 PM
$GOSS what a dog
0 · Reply
Partyflags
Partyflags May. 29 at 9:08 AM
$GOSS
0 · Reply
Zing43
Zing43 May. 29 at 3:38 AM
$GOSS
0 · Reply
Bullishontherize
Bullishontherize May. 29 at 12:48 AM
$GOSS Short Borrow Fee on the rise! Greedy pigs get slaughtered soon!
0 · Reply
Kyera93
Kyera93 May. 28 at 4:00 PM
$GOSS wake up
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits May. 28 at 3:06 PM
$GOSS I can only hope that when this sock finally gets its wings their gif library will include clips of the gossamer albatross for long's postings.
0 · Reply
Zackpedia
Zackpedia May. 28 at 3:02 PM
$GOSS Should retest the .16 support soon
0 · Reply
Uw1n91
Uw1n91 May. 28 at 1:49 PM
$GOSS And safe/effective in sick patients. My bear case- FDA rejects them, J&J and Merck bid for their IP, sell for $500M (so effectively .50-60 stock price after debt). Bull case- FDA fast tracks for sick pop, drug on market mid ‘27 ($10 PT / $5B val or acquired)……or somewhere in between. So, 3X in bear scenario, 25-50X bull
2 · Reply
Lupin00
Lupin00 May. 28 at 10:02 AM
$GOSS BlackRock own 15.065.708 shares of Gossamer Bio, that are 6,4% I think they know something.
0 · Reply
Zing43
Zing43 May. 28 at 4:37 AM
$GOSS buy this
0 · Reply
DocKnocks
DocKnocks May. 27 at 9:52 PM
$GOSS this will be back above $1 very soon
0 · Reply
Sharelord
Sharelord May. 27 at 6:37 PM
$GOSS RS is reality unless mgmt has good Fda meeting and Nda submission in the autumn. We need safe zone 1.5 to 2$ to Nasdaq approval for further listing. There are also new rules for reverse split on Nyse and Nasdaq so it is no more simple as before in some biotech companies. Hopfully GOSS didn't have one and will be better to go along without it
1 · Reply
Addihaa
Addihaa May. 27 at 5:48 PM
$GOSS RS this by 10 so it can drop another 90% pls , ty
0 · Reply
AlexRo777
AlexRo777 May. 27 at 4:59 PM
$GOSS biotech is so bullish today, but this is in a different planet, it’s trash since they removed it from etf too… next bankruptcy there’s no escape
0 · Reply
Lupin00
Lupin00 May. 27 at 4:04 PM
$GOSS Added more!
1 · Reply